A potential merger between Slovak health insurers Dôvera and Union may avoid a comprehensive review by competition authorities, both national and European. The case hinges on a prior court ruling establishing that Slovak health insurance companies are not considered standard businesses. This precedent could exempt Penta’s acquisition of Union from detailed antitrust assessment. Concerns have been raised since Penta announced its intention to purchase Union, prompting questions about market dominance. The unique status of health insurers in Slovak law may allow the deal to proceed with minimal regulatory hurdles. This outcome raises questions about competition within Slovakia’s healthcare market. Ultimately, the deal’s fate rests on how regulators interpret the existing legal framework regarding healthcare providers.